Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Latest news

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Analyst Ratings
  • Markets
  • News
  • Penny Stocks
  • Pre-Market Outlook
  • Price Target
  • Small Cap

HC Wainwright Cuts Price Target On This Stock By 73%, Also Check Out Other Major PT Changes Here

By Lisa Levin
September 12, 8:44 AM
Susquehanna cut the price target on Baidu, Inc. (NASDAQ: BIDU) from $200 to $195. Susquehanna analyst Shyam Patil maintained the stock with a Positive rating. Baidu shares rose 0.7% to $139.38 in pre-market trading.

BIDU

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

Barclays Maintains Overweight on Thermo Fisher Scientific, Lowers Price Target to $595

By Benzinga Newsdesk
September 12, 7:13 AM
Barclays analyst Luke Sergott maintains Thermo Fisher Scientific (NYSE:TMO) with a Overweight and lowers the price target from $685 to $595.

TMO

Read More
3 minute read
  • General
  • News
  • Politics

Trump Ally Dr. Oz Hyped Unapproved ‘Covid Cures’ From Companies He Owns Shares Of

By Chris Katje
September 8, 11:42 AM
Republican Pennsylvania Senate candidate Dr. Mehmet Oz owns shares of two companies he publicly supported, touting their drugs as potential Covid-19 treatments — even though the drugs weren't approved by the U.S. Food and Drug Administration (FDA).

MCK

Read More
2 minute read
  • Markets
  • Options

Check Out What Whales Are Doing With TMO

By Benzinga Insights
September 1, 2:18 PM
Someone with a lot of money to spend has taken a bearish stance on Thermo Fisher Scientific (NYSE:TMO). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

TMO

Read More
1 minute read
  • General
  • Government
  • Health Care
  • News
  • Top Stories

No More Free COVID-19 At-Home Tests, Federal Government Says

By Vandana Singh
August 29, 8:20 AM
CNBC reported that the federal government is set to suspend its offer of free at-home COVID-19 tests by Friday, September 2, without congressional au

A

Read More
1 minute read
  • Analyst Ratings

Expert Ratings for Thermo Fisher Scientific

By Benzinga Insights
August 25, 11:10 AM
Over the past 3 months, 5 analysts have published their opinion on Thermo Fisher Scientific (NYSE:TMO) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

TMO

Read More
1 minute read
  • Analyst Ratings

What 5 Analyst Ratings Have To Say About Thermo Fisher Scientific

By Benzinga Insights
August 25, 10:35 AM
Thermo Fisher Scientific (NYSE:TMO) has observed the following analyst ratings within the last quarter:

TMO

Read More
14 minute read
  • Analyst Ratings
  • Downgrades
  • Initiation
  • Intraday Update
  • Upgrades

Benzinga’s Top Ratings Upgrades, Downgrades For August 25, 2022

By Benzinga Insights
August 25, 10:34 AM
Upgrades

A

Read More
4 minute read
  • Options

10 Health Care Stocks Whale Activity In Today’s Session

By Benzinga Insights
August 17, 1:36 PM
  This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

A

Read More
1 minute read
  • Dividends
  • Earnings
  • News

Here’s How Much $1000 Invested In Thermo Fisher Scientific 20 Years Ago Would Be Worth Today

By Benzinga Insights
August 4, 2:52 PM
Thermo Fisher Scientific (NYSE:TMO) has outperformed the market over the past 20 years by 11.6% on an annualized basis producing an average annual return of 19.59%. Currently, Thermo Fisher Scientific has a market capitalization of $230.17 billion.

TMO

Posts pagination

Previous 1 … 20 21 22 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service